Foresite Capital Management Vi LLC Top Holdings and 13F Report (2026) About Foresite Capital Management Vi LLCInvestment ActivityForesite Capital Management Vi LLC has $460.27 million in total holdings as of March 31, 2026.Foresite Capital Management Vi LLC owns shares of 17 different stocks, but just 7 companies or ETFs make up 80% of its holdings.Approximately 15.42% of the portfolio was purchased this quarter.About 17.33% of the portfolio was sold this quarter.This quarter, Foresite Capital Management Vi LLC has purchased 12 new stocks and bought additional shares in 4 stocks.Foresite Capital Management Vi LLC sold shares of 1 stock and completely divested from 3 stocks this quarter.Largest Holdings CG Oncology, Inc. $150,349,360ALUMIS INC. $93,576,170Centessa Pharmaceuticals $54,178,835Corvus Pharmaceuticals $26,790,939Denali Therapeutics $23,231,443 Largest New Holdings this Quarter 603380205 - Minerva Neurosciences $11,969,265 Holding15117B202 - Celldex Therapeutics $10,020,760 Holding04650F101 - AtaiBeckley Inc. $9,735,000 Holding22663K107 - Crinetics Pharmaceuticals $7,700,203 Holding68277Q105 - OnKure Therapeutics, Inc. $5,985,542 Holding Largest Purchases this Quarter Minerva Neurosciences 1,986,600 shares (about $11.97M)Celldex Therapeutics 315,913 shares (about $10.02M)AtaiBeckley Inc. 2,750,000 shares (about $9.74M)Crinetics Pharmaceuticals 212,010 shares (about $7.70M)Corvus Pharmaceuticals 450,000 shares (about $6.58M) Largest Sales this Quarter Agios Pharmaceuticals 5,000 shares (about $169.15K) Sector Allocation Over TimeMap of 500 Largest Holdings ofForesite Capital Management Vi LLC Selling Neutral Buying Latest 13F Holdings and Changes Since Previous Quarterly FilingIssuer NameHoldings ValueApproximate Purchase/SaleChange in SharesShares Held% of PortfolioSectorCG Oncology, Inc.$150,349,3600.0%2,221,47432.7%COMALUMIS INC.$93,576,1700.0%4,247,67020.3%COMCNTACentessa Pharmaceuticals$54,178,8350.0%1,364,01911.8%MedicalCRVSCorvus Pharmaceuticals$26,790,939$6,583,500 â–²32.6%1,831,2335.8%MedicalDNLIDenali Therapeutics$23,231,443$4,031,443 â–²21.0%1,209,9715.0%MedicalAGIOAgios Pharmaceuticals$17,760,750$169,150 â–¼-0.9%525,0003.9%MedicalVSTMVerastem$16,677,144$61,008 â–²0.4%3,146,6313.6%MedicalKYMRKymera Therapeutics$12,187,9920.0%146,3322.6%MedicalNERVMinerva Neurosciences$11,969,265$11,969,265 â–²New Holding1,986,6002.6%MedicalCLDXCelldex Therapeutics$10,020,760$10,020,760 â–²New Holding315,9132.2%MedicalAtaiBeckley Inc.$9,735,000$9,735,000 â–²New Holding2,750,0002.1%COMHinge Health, Inc.$8,498,624$3,293,024 â–²63.3%220,4001.8%CL ACRNXCrinetics Pharmaceuticals$7,700,203$7,700,203 â–²New Holding212,0101.7%MedicalOnKure Therapeutics, Inc.$5,985,542$5,985,542 â–²New Holding1,445,7831.3%COM CL AJade Biosciences, Inc.$4,496,000$4,496,000 â–²New Holding320,0001.0%COMGHRSGH Research$4,435,818$4,435,818 â–²New Holding315,4921.0%MedicalZURAZura Bio$2,677,500$2,677,500 â–²New Holding450,0000.6%MedicalRAPT Therapeutics, Inc.$0$52,921,875 â–¼-100.0%00.0%COMNTRANatera$0$15,430,586 â–¼-100.0%00.0%MedicalATAIAtai Beckley$0$11,247,500 â–¼-100.0%00.0%MedicalShowing largest 100 holdings. View all holdings. More Institutional Buying and Selling Information SEC Filings and Trading Data SEC Filings 13F Filings Top 13F Buys Top 13F Sells Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
